Context Therapeutics annual free cash flow
2021
2022
2023
2024
2025
Context Therapeutics Free Cash Flow (FCF) History (CNTX)
Context Therapeutics reported −$26.4M in free cash flow for fiscal 2025, a decrease of $11.9M from the previous fiscal year.
View full Context Therapeutics company overviewContext Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$26.4M | −$11.9M | — | — |
| 2024 | 2024-12-31 | −$14.6M | $6.5M | — | — |
| 2023 | 2023-12-31 | −$21.0M | −$7.5M | — | — |
| 2022 | 2022-12-31 | −$13.6M | −$4.8M | — | — |
| 2021 | 2021-12-31 | −$8.8M | — | — | — |
Context Therapeutics quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$7.0M | −$1.2M | — | — |
| Q1 2026 | 2026-03-31 | −$11.5M | −$6.4M | — | — |
| Q4 2025 | 2025-12-31 | −$8.9M | −$4.0M | — | — |
| Q3 2025 | 2025-09-30 | −$6.6M | −$4.6M | — | — |
| Q2 2025 | 2025-06-30 | −$5.8M | −$2.5M | — | — |
| Q1 2025 | 2025-03-31 | −$5.1M | −$701,709 | — | — |
| Q4 2024 | 2024-12-31 | −$4.9M | $2.3M | — | — |
| Q3 2024 | 2024-09-30 | −$1.9M | $1.5M | — | — |
| Q2 2024 | 2024-06-30 | −$3.4M | $1.3M | — | — |
| Q1 2024 | 2024-03-31 | −$4.4M | $1.4M | — | — |
| Q4 2023 | 2023-12-31 | −$7.2M | −$3.3M | — | — |
| Q3 2023 | 2023-09-30 | −$3.5M | −$466,788 | — | — |
| Q2 2023 | 2023-06-30 | −$4.6M | −$1.8M | — | — |
| Q1 2023 | 2023-03-31 | −$5.7M | −$1.9M | — | — |
| Q4 2022 | 2022-12-31 | −$3.9M | $1.0M | — | — |
| Q3 2022 | 2022-09-30 | −$3.0M | −$3.0M | — | — |
| Q2 2022 | 2022-06-30 | −$2.8M | −$728,102 | — | — |
| Q1 2022 | 2022-03-31 | −$3.9M | −$2.1M | — | — |
| Q4 2021 | 2021-12-31 | −$5.0M | — | — | — |
| Q3 2021 | 2021-09-30 | −$43,633 | — | — | — |
| Q2 2021 | 2021-06-30 | −$2.1M | — | — | — |
| Q1 2021 | 2021-03-31 | −$1.7M | — | — | — |
Context Therapeutics free cash flow growth trends
Context Therapeutics's latest reported quarter, Q2 2026, generated −$7.0M in free cash flow, a decrease of $1.2M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Context Therapeutics filings at SEC.gov ↗